Sobel Alan D.

SEC source: 0001104659-26-108246 · tm2625479-2_4seq1.xml · nonDerivative · entry 3

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,887

F1 · balance_after: These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of CytoSorbents Corporation (the "Issuer"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person.

F3 · balance_after: Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

SEC source: 0001104659-26-108246 · tm2625479-2_4seq1.xml · nonDerivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,787

F1 · balance_after: These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of CytoSorbents Corporation (the "Issuer"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person.

F3 · balance_after: Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

SEC source: 0001104659-26-108246 · tm2625479-2_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,287

F1 · balance_after: These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of CytoSorbents Corporation (the "Issuer"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person.

F3 · balance_after: Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

SEC source: 0001104659-25-075790 · tm2522995-5_4seq1.xml · derivative · entry 3

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2035-08-08

F3 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-25-017618 · tm257709-5_4seq1.xml · derivative · entry 3

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,950 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the Reporting Person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · derivative.exercise_price: The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

SEC source: 0001104659-25-017618 · tm257709-5_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,757

F1 · security: On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the Reporting Person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · price: The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F3 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 76,457 shares of Common Stock owned directly by the Reporting Person.

SEC source: 0001104659-25-005354 · tm254168-1_4seq1.xml · derivative · entry 5

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,950

Underlying: Common Stock · 21,950 shares

Expires 2025-04-10

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F6 · derivative.exercise_price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F6 · price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F7 · derivative.expiration_date: The Series B Right Warrants expire 90 calendar days following the Closing Date.

SEC source: 0001104659-25-005354 · tm254168-1_4seq1.xml · derivative · entry 4

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,950

Underlying: Common Stock · 21,950 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F4 · derivative.exercise_price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F4 · price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F5 · derivative.expiration_date: The Series A Right Warrants expire 45 calendar days following the Closing Date.

SEC source: 0001104659-25-005354 · tm254168-1_4seq1.xml · derivative · entry 3

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,950 shares

Expires 2025-01-10

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").

SEC source: 0001104659-25-005354 · tm254168-1_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,807

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F1 · price: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 32,557 shares of Common Stock owned directly by the reporting person.

SEC source: 0001104659-24-043794 · tm2411149-8_4seq1.xml · derivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-04-02

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-126432 · tm2332958-5_4seq1.xml · derivative · entry 3

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,894

Underlying: Common Stock · 7,894 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126432 · tm2332958-5_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,857

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 32,557 shares of Common Stock owned directly by the reporting person.

SEC source: 0001104659-23-080103 · tm2321021-5_4seq1.xml · derivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-07-07

F2 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options shall vest in full on the first anniversary of the award date, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-027440 · tm238212-1_4seq1.xml · nonDerivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Bernard Sobel Revocable Trust

Disclosed balance after: 0

F1 · kind: Reflects the transfer of shares to the reporting person from the Bernard Sobel Revocable Trust (the "Trust"), for which the reporting person is a trustee and a named beneficiary.

F1 · ownership.nature: Reflects the transfer of shares to the reporting person from the Bernard Sobel Revocable Trust (the "Trust"), for which the reporting person is a trustee and a named beneficiary.

SEC source: 0001104659-23-027440 · tm238212-1_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,300

F1 · kind: Reflects the transfer of shares to the reporting person from the Bernard Sobel Revocable Trust (the "Trust"), for which the reporting person is a trustee and a named beneficiary.

F2 · balance_after: Includes (i) the following restricted stock units that will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 restricted stock units granted on March 15, 2018, (b) 6,000 restricted stock units granted on February 24, 2017, (c) 5,000 restricted stock units granted on June 7, 2016, and (d) 55,000 restricted stock units granted on April 8, 2015 and (ii) 12,000 shares of common stock owned directly by the reporting person.

SEC source: 0001104659-22-090262 · tm2223355d10_4seq1.xml · derivative · entry 3

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,975

Underlying: Common Stock · 18,975 shares

Expires 2032-08-10

F3 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four equal parts on 8/10/2022, 9/30/2022, 12/31/2022 and 3/31/2023, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-059474 · tm2215403d1_4seq1.xml · nonDerivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,300

F1 · balance_after: Includes (i) the following restricted stock units that will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 restricted stock units granted on March 15, 2018, (b) 6,000 restricted stock units granted on February 24, 2017, (c) 5,000 restricted stock units granted on June 7, 2016, and (d) 55,000 restricted stock units granted on April 8, 2015 and (ii) 10,000 shares of common stock purchased by the reporting person on May 11, 2022 and reported on this Form 4.

SEC source: 0001104659-22-059474 · tm2215403d1_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,500

SEC source: 0001104659-22-023820 · tm226775d1_4.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Bernard Sobel Revocable Trust

Disclosed balance after: 2,000

F1 · ownership.nature: These shares are held in the Bernard Sobel Revocable Trust (the "Trust'"). On February 14, 2022, the reporting person became a trustee of the Trust. The reporting person is also a named beneficiary of the Trust. Accordingly, the reporting person may be deemed the beneficial owner of the shares held in the Trust.

SEC source: 0001104659-21-050402 · tm2113016d8_4.xml · derivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,250

Underlying: Common Stock · 17,250 shares

Expires 2031-04-12

F1 · derivative.exercise_date: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options will vest in four equal parts on 4/12/2021, 6/30/2021, 9/30/2021 and 12/31/2021, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-20-028656 · tm2011575d8_form4.xml · derivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-02-28

F1 · derivative.exercise_date: Includes 15,000 stock options granted on 2/28/2020 and reported on this Form 4. These options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and will vest in four equal parts on 3/31/2020, 6/30/2020, 9/30/2020 and 12/31/2020.

F1 · balance_after: Includes 15,000 stock options granted on 2/28/2020 and reported on this Form 4. These options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and will vest in four equal parts on 3/31/2020, 6/30/2020, 9/30/2020 and 12/31/2020.

SEC source: 0001144204-19-035839 · tv525805_4.xml · derivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-07-22

F1 · derivative.exercise_date: Such options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan and vest in four equal parts at the end of each calendar quarter. The grant gives effect to vesting which was to occur on March 31, 2019 and June 30, 2019. The remaining portion of the grant will vest on September 30, 2019 and December 31, 2019.

SEC source: 0001144204-18-022970 · tv492277_4.xml · derivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,450

Underlying: Common Stock · 14,450 shares

Expires 2028-03-15

F3 · derivative.exercise_date: Such options were granted pursuant to the Plan and vest in four equal parts at the end of each calendar quarter beginning January 1, 2018.

SEC source: 0001144204-18-022970 · tv492277_4.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,300

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change in Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan").

F2 · balance_after: Includes the following restricted stock units subject to vesting in accordance with the schedule set forth in (1) above: (a) 3,300 restricted stock units granted on March 15, 2018 and reported on this Form 4, (b) 6,000 restricted stock units granted on February 24, 2017, (c) 5,000 restricted stock units granted on June 7, 2016, and (d) 55,000 restricted stock units granted on April 8, 2015.

SEC source: 0001144204-17-011825 · v460705_4.xml · derivative · entry 2

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2027-02-24

F3 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which vest in four equal parts at the end of each calendar quarter beginning April 1, 2017.

SEC source: 0001144204-17-011825 · v460705_4.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,000

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.

F2 · balance_after: Includes (i) 6,000 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 5,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 55,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (1) above.